In a EU‑Startups podcast, PrintyMed founder and CEO Jekaterina Romanova discussed the Latvian biotech startup’s biomimetic spider‑silk technology, its €2 million in EU grant funding, and plans to expand into Saudi Arabia while focusing on organ‑on‑a‑chip membranes for drug testing.
Helsinki‑based AI life‑science startup Aiforia obtained €20 million of venture debt from the European Investment Bank, backed by the EU InvestEU programme, to speed up its AI‑driven cancer diagnostic platform and grow its global commercial presence.
Slovenian genomics and laboratory company GenePlanet secured a strategic investment from Lauxera Capital Partners. The deal also saw early investor BlackPeak Capital partially exit while staying on the cap table, providing GenePlanet with additional capital to expand its genetic testing and next‑generation sequencing services across Europe.
Clinica Prevencia is building a technology‑enabled medical operator that links its clinics, mobile ambulance service and AI assistant to standardise, automate and connect processes, aiming for a scalable, data‑driven healthcare platform.
Clean Cells, a French biopharma quality‑control provider founded in 2020, announced the acquisition of Anaquant, a specialist CRO in mass‑spectrometry‑based protein analysis. The deal, terms undisclosed, gives Clean Cells ownership of Anaquant’s brand, IP, analytics platform and ReadyBeads technology, strengthening its capability to deliver protein characterization and host‑cell‑protein profiling for regulatory submissions.
Zonova Technologies, a UK healthtech startup, participated in a free five‑day entrepreneurship course for teenagers in London, where its CEO Georgia Fleet presented a pitch and noted she had just closed a seed‑stage funding round.
Dutch‑US medtech startup Xeltis secured an additional €20.5 million, led by Horizon 3 Healthcare, to push forward its living‑tissue vascular implants, complete a pivotal US trial, and scale European commercialization and manufacturing.
Spanish deep‑tech startup Onalabs raised over €9.3 million, led by the Spanish Society for Technological Transformation (SETT), to accelerate the rollout of its non‑invasive, sweat‑based health monitoring platform across Europe.
The article describes how Emilia Lewicka, after more than ten years of searching for a diagnosis for chronic pelvic pain, co‑founded the Polish startup Heliax in Wrocław. The company aims to reduce the costly and lengthy diagnostic process—often exceeding 50,000 PLN—by offering the Vitabloom solution, thereby shortening patients’ years of uncertainty.
Nabla announced a leadership transition, with founder Alexandre Lebrun handing over the CEO role to Brian Manning.